Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 5/20 | 0.66 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.66 |
| ▸ | HTR6 | P50406 | 13/20 | 0.53 |
| ▸ | PPARG | P37231 | 2/20 | 0.50 |
| ▸ | PPARD | Q03181 | 2/20 | 0.50 |
| ▸ | PPARA | Q07869 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18222552 | 0.88 | MTNR1A (0.51) | MTNR1AMTNR1BHTR6PPARGPPARD | |
| SCHEMBL18239835 | 0.87 | MTNR1A (0.47) | MTNR1AMTNR1BHTR6 | |
| SCHEMBL18239758 | 0.86 | MTNR1A (0.48) | MTNR1AMTNR1BHTR6 | |
| SCHEMBL18239759 | 0.85 | MTNR1A (0.52) | MTNR1AMTNR1BHTR6 | |
| SCHEMBL18222499 | 0.83 | MTNR1A (0.47) | MTNR1AMTNR1BHTR6PPARGPPARD | |
| SCHEMBL20514298 | 0.81 | MTNR1A (0.43) | MTNR1AMTNR1BHTR6 | |
| SCHEMBL18239683 | 0.81 | MTNR1A (0.43) | MTNR1AMTNR1BHTR6 | |
| SCHEMBL18239706 | 0.81 | MTNR1A (0.43) | MTNR1AMTNR1BHTR6 | |
| SCHEMBL3017284 | 0.80 | HTR6 (0.68) | MTNR1AMTNR1BHTR6PPARGPPARD | |
| SCHEMBL18239852 | 0.80 | MTNR1A (0.43) | MTNR1AMTNR1BHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637451-B2 | Indole compound | ASTELLAS PHARMA INC. (JP) | 2017-05-02 | — | — | US | disclosed |
| EP-3095781-A1 | INDOLE COMPOUND | Astellas Pharma Inc. (JP) | 2016-11-23 | — | — | EP | disclosed |
| US-20160332966-A1 | INDOLE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2016-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160332966-A1 | INDOLE COMPOUND | MTNR1A, MTNR1B, IDO2 | MTNR1A 1/4885MTNR1B 2/4885HTR6 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.